



WD

Gp 1638/1\$
Box 589

Attorney Docket No. 4001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Eduardo BLUMWALD et al. | Art Unit: 1638
Serial No.: 09/271,584 |
Filed: March 18, 1999 | Examiner: A. Kubelik
For: GENETIC ENGINEERING
SALT TOLERANCE IN CROP PLANTS |

RECEIVED

FEB 08 2001

TECH CENTER 1500/2900

RECEIVED

FEB 12 2001

TECH CENTER 1600/2900

TRANSMITTAL LETTER

To The Assistant Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

In response to the Communication of November 29, 2000, please find enclosed the following:

- X Copy of Notice to Comply with Sequence Listing Requirements, including four attachments to Notice.
- X Amendment
- X Statement in Support of Filing
- X Sequence Listing: hard copy and disk copy
- X Request for Extension of Time
- X Check in the amount of \$110.00 for extension of time

Respectfully submitted,

Date:

Jan 29, 2001

By

Patricia A. Sweeney

Patricia A. Sweeney
Registration No. 32,733
Attorney for Applicants

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this Amendment is being deposited on the date shown below with the United States Postal Service first class mail, addressed to the Assistant Commissioner for Patents, U.S. Patent & Trademark Office, Washington, D.C. 20231.

1/29/01
Date

Patricia A. Sweeney
Patricia A. Sweeney



Notice to Comply

Application No.	Applicant(s)	
09/271,584	BLUMWALD ET AL.	
Examiner	Art Unit	
Anne R. Kubelik,	1638	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

TECH CENTER 1600/2300

FEB 12 2001

RECEIVED



Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 04/271,584

- ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE
- 1 ☐ Wrapped Nucleics
The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
 - 2 ☐ Wrapped Aminos
The amino acid number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
 - 3 ☐ Incorrect Line Length
The rules require that a line not exceed 72 characters in length. This includes spaces.
 - 4 ☐ Misaligned Amino Acid Numbering
The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
 - 5 ☐ Non-ASCII
This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
 - 6 ☐ Variable Length
Sequence(s) _____ contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.
 - 7 ☐ PatentIn ver. 2.0 "bug"
A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
 - 8 ☐ Skipped Sequences (OLD RULES)
Sequence(s) _____ missing. If intentional, please use the following format for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
 - 9 ☐ Skipped Sequences (NEW RULES)
Sequence(s) _____ missing. If intentional, please use the following format for each skipped sequence.
<210> sequence id number
<400> sequence id number
000
 - 10 ☒ Use of n's or Xaa's (NEW RULES)
Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
 - 11 ☐ Use of <213>Organism (NEW RULES)
Sequence(s) _____ are missing this mandatory field or its response.
 - 12 ☐ Use of <220>Feature (NEW RULES)
Sequence(s) _____ are missing the <220>Feature and associated headings.
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
 - 13 ☐ PatentIn ver. 2.0 "bug"
Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other means to copy file to floppy disk.